arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Sarepta Therapeutics, Inc.

SRPT
$17.54 ▼ -1.46 (-7.68%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
70 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Sarepta Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.8B
Dividend Yield —
Revenue Growth -34.3% ↘
Op. Margin 3.3% ↘
ROIC 1.6% ↘
FCF / Share $1.86 ↗
Trailing P/E —
Price / Book 1.2x
FCF Yield 10.6%
Debt / Equity 0.55
info Valuation on last close. End-of-day price, Nov 5, 2026.

70-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$401.25M
↓ -34.3% —
Net Income Profit after all expenses
$330.96M
— 0.0% —
Operating Margin Operating profit as % of sales
3.3%
↓ -93.2% 7th
FCF / Share Free cash flow per share
$1.86
↓ -20.4% —
Long-Term Debt Long-term obligations
$847.62M
↑ +1.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↓
14
Financial Health ↓
52
Cash Quality ↓
37

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 70 quarters